Dynavax Technologies Corp. (DVAX) Reaches New 1-Year Low at $10.14
Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.14 and last traded at $10.91, with a volume of 15,812,601 shares changing hands. The stock had previously closed at $15.94.
DVAX has been the subject of several recent research reports. S&P Equity Research increased their price target on Dynavax Technologies Corp. from $11.28 to $16.01 in a report on Friday. Zacks Investment Research upgraded Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, May 25th.
The firm’s 50 day moving average is $15.61 and its 200 day moving average is $16.74. The firm’s market capitalization is $420.00 million.
Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.07. During the same quarter in the previous year, the business earned ($0.80) earnings per share. The company had revenue of $2.65 million for the quarter, compared to the consensus estimate of $1.58 million. The company’s revenue was up 70.8% compared to the same quarter last year. Analysts predict that Dynavax Technologies Corp. will post ($2.96) EPS for the current fiscal year.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.